OncoZenge shared a post on LinkedIn:
“OncoZenge has announced an important key milestone: the submission of the Clinical Trial Application (CTA) for our Phase III study of BupiZenge.
In connection with this milestone, OncoZenge has also resolved on a directed share issue to Sichuan Yangtian Biological Pharmaceutical, pursuant to the investment agreement. This strengthens our financial position and supports the continued execution of the Phase III program.
Together, these steps represent significant progress in OncoZenge’s clinical and strategic development as the company advances BupiZenge toward late-stage clinical development and regulatory approval.
OncoZenge would like to thank LINK Medical, acting as Contract Research Organization (CRO), for its valuable support in site identification, preparation of clinical documentation, and CTA submission.
Read the full release about the CTA submission.
Read the full release about the directed share issue.”
For more oncology insights, you can explore additional content on OncoDaily.